#AAPP2026 Spotlight: Medication Treatment of Social Anxiety Disorder: Beyond Serotonin Reuptake Inhibitors, presented by Franklin Schneier, MD
Current clinical guidelines offer limited direction beyond the use of FDA-approved SSRIs and SNRIs, particularly regarding novel treatments like antipsychotics and ketamine. This session examines the evolving evidence surrounding off-label medications for social anxiety, highlighting the research that suggests a potential role for these agents in select patients. Join us at the 2026 AAPP Annual Meeting in Bellevue, WA, on Seattle’s Eastside, for this session!
#AAPP #psychpharmacy #acpe #bcpp #bcpmp